Peptron Inc
KOSDAQ:087010
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Peptron Inc
Total Liabilities
Peptron Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Total Liabilities
₩37.4B
|
CAGR 3-Years
35%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
24%
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Total Liabilities
₩6.2T
|
CAGR 3-Years
-7%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Total Liabilities
₩11.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Liabilities
₩231.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Liabilities
₩19.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Liabilities
₩145.5B
|
CAGR 3-Years
66%
|
CAGR 5-Years
49%
|
CAGR 10-Years
27%
|
|
Peptron Inc
Glance View
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
See Also
What is Peptron Inc's Total Liabilities?
Total Liabilities
37.4B
KRW
Based on the financial report for Dec 31, 2025, Peptron Inc's Total Liabilities amounts to 37.4B KRW.
What is Peptron Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
24%
Over the last year, the Total Liabilities growth was 88%. The average annual Total Liabilities growth rates for Peptron Inc have been 35% over the past three years , -2% over the past five years , and 24% over the past ten years .